Lorundrostat not checked
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Hypertension
- Main trialPhase 3
- “This study is to evaluate the long-term safety, efficacy and tolerability of lorundrostat (an aldosterone synthase inhibitor) in subjects with hypertension”In the company’s words, NCT05968430 on ClinicalTrials.gov
Other drugs for Hypertension
- BaxdrostatAstraZeneca · Phase 3
- BR1019Boryung Pharmaceutical Co., Ltd · Phase 3
- CagriSemaNovo Nordisk · Phase 3
- RalinepagUnited Therapeutics · Phase 3
- OrforglipronEli Lilly · Phase 3
- HCP1803-3Hanmi · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials5
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 30 Dec 2025 | Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension | |
| Phase 3Completed | 10 Dec 2024 | Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension | |
| Phase 2Completed | 15 Jan 2025 | A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen | |
| Phase 2Completed | 27 Feb 2025 | Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria | |
| Phase 2Completed | 17 Dec 2025 | A Study to Assess the Efficacy and Safety of Lorundrostat in Participants With Obstructive Sleep Apnea and Hypertension |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026